Skip to main content

Resmed (RMD) Receives a Hold from Stifel Nicolaus

Tipranks - Tipranks - Sat Jan 31, 6:56AM CST

In a report released today, Jonathan Block from Stifel Nicolaus maintained a Hold rating on Resmed, with a price target of $265.00.

Claim 50% Off TipRanks Premium

According to TipRanks, Block is a 4-star analyst with an average return of 6.5% and a 52.14% success rate. Block covers the Healthcare sector, focusing on stocks such as Zoetis, Elanco Animal Health, and Idexx Laboratories.

In addition to Stifel Nicolaus, Resmed also received a Hold from Needham’s Michael Matson in a report issued today. However, on the same day, KeyBanc maintained a Buy rating on Resmed (NYSE: RMD).

See today’s best-performing stocks on TipRanks >>

Based on Resmed’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.42 billion and a net profit of $392.59 million. In comparison, last year the company earned a revenue of $1.28 billion and had a net profit of $344.62 million

Read More on RMD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).